[Video] Principles of cognitive safety assessment in clinical development

Posted on 7 May 2015 in Clinical Trials

Dr Kenton Zavitz, Director of Clinical Affairs presented at the 7th Annual World Drug Safety Congress in Chicago, on the 22nd April 2015. Speaking to an international audience of drug safety and pharmacovigilance experts, Dr. Zavitz, highlighted new evidence that many drugs treating conditions including cardiovascular disease, allergies, diabetes and cancer may result in cognitive impairment with potentially serious consequences for patient safety. Dr Zavitz called for these effects to be monitored closely and fully characterized in the drug development process with monitoring continuing once such drugs are used routinely, particularly in vulnerable populations such as the elderly.